NCT00787605View on ClinicalTrials.gov

Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus

PHASE4CompletedINTERVENTIONAL
Enrollment

860

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
HypertensionDiabetes Mellitus
Interventions
DRUG

Amlodipine

Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks

DRUG

Hydrochlorothiazide (HCTZ)

Hydrochlorothiazide 12.5 mg for 1 week followed by Hydrochlorothiazide 25 mg for 7 weeks

DRUG

Aliskiren

Aliskiren 150 mg for 1 week followed by Aliskiren 300 mg for 7 weeks

Trial Locations (1)

07936

Sites in USA, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00787605 - Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus | Biotech Hunter | Biotech Hunter